Synopsis
Synopsis
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Apimid
2. Apo Flutamide
3. Apo-flutamide
4. Apoflutamide
5. Chimax
6. Cytamid
7. Drogenil
8. Euflex
9. Eulexin
10. Eulexine
11. Fluken
12. Flulem
13. Flumid
14. Fluta 1a Pharma
15. Fluta Cell
16. Fluta Gry
17. Fluta-cell
18. Fluta-gry
19. Flutacell
20. Flutagry
21. Flutamin
22. Flutandrona
23. Flutaplex
24. Flutexin
25. Fugerel
26. Grisetin
27. Niftolid
28. Niftolide
29. Novo Flutamide
30. Novo-flutamide
31. Novoflutamide
32. Oncosal
33. Pms Flutamide
34. Pms-flutamide
35. Prostacur
36. Prostica
37. Prostogenat
38. Sch 13521
39. Sch-13521
40. Sch13521
41. Testotard
1. 13311-84-7
2. Eulexin
3. Niftolide
4. Niftholide
5. Sch 13521
6. 2-methyl-n-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
7. Nfba
8. Niftolid
9. Drogenil
10. Flutamin
11. Cebatrol, Veterinary
12. Flutamida
13. Flutamidum
14. Sch-13521
15. 4'-nitro-3'-trifluoromethylisobutyranilide
16. 2-methyl-n-(4-nitro-3-[trifluoromethyl]phenyl)propanamide
17. N-(4-nitro-3-(trifluoromethyl)phenyl)isobutyramide
18. Sch13521
19. Mfcd00072009
20. Nsc 215876
21. Flutamide (eulexin)
22. Alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-m-propionotoluidide
23. Chembl806
24. Propanamide, 2-methyl-n-(4-nitro-3-(trifluoromethyl)phenyl)-
25. Propanamide, 2-methyl-n-[4-nitro-3-(trifluoromethyl)phenyl]-
26. Nsc-215876
27. 4-nitro-3-(trifluoromethyl)isobutyranilide
28. Chebi:5132
29. 76w6j0943e
30. Ncgc00015452-09
31. Eulexine
32. Chimax
33. 4'-nitro-3'-trifluoromethylisobutyramilide
34. Cas-13311-84-7
35. Ham's F-12 Medium
36. Flutamidum [inn-latin]
37. Dsstox_cid_11121
38. Dsstox_rid_78899
39. Dsstox_gsid_32004
40. Flutamida [inn-spanish]
41. Flutamide Usp25
42. N-[4-nitro-3-(trifluoromethyl)phenyl]isobutyramide
43. Prostandril
44. Odyne
45. .alpha.,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro-m-propionotoluidide
46. Smr000058187
47. Eulexin (tn)
48. Ccris 7246
49. M-propionotoluidide,.alpha.,.alpha.-trifluoro-
50. Sr-01000075888
51. 4'-nitro-3'-(trifluoromethyl)isobutyranilide
52. Einecs 236-341-9
53. Brn 2157663
54. .alpha.,.alpha.-trifluoro-2-methyl-4'-nitro-m-propionotoluidide
55. M-propionotoluidide,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro-
56. Unii-76w6j0943e
57. Flutamide [usan:usp:inn:ban]
58. Flutamide,(s)
59. Prestwick_228
60. Nk-601
61. Spectrum_001210
62. 2-methyl-n-[4-nitro-3-(trifluoromethyl)phenyl]propionamide
63. Cpd000058187
64. Flutamide [inn]
65. Flutamide [jan]
66. Flutamide [mi]
67. Flutamide [usan]
68. Prestwick0_000180
69. Prestwick1_000180
70. Prestwick2_000180
71. Prestwick3_000180
72. Spectrum2_001201
73. Spectrum3_001421
74. Spectrum4_000829
75. Spectrum5_001450
76. Lopac-f-9397
77. F0663
78. Flutamide (pubertal Study)
79. Flutamide [mart.]
80. F 9397
81. Flutamide [usp-rs]
82. Flutamide [who-dd]
83. Schembl3934
84. Lopac0_000557
85. Bspbio_000079
86. Bspbio_003122
87. Kbiogr_001377
88. Kbioss_001690
89. Mls000069634
90. Mls001065596
91. Mls002548892
92. Divk1c_000459
93. Spectrum1500995
94. Spbio_000982
95. Spbio_002000
96. Flutamide (jp17/usp/inn)
97. Bpbio1_000087
98. Gtpl6943
99. Flutamide [ep Impurity]
100. Flutamide [orange Book]
101. Chembl4759307
102. Dtxsid7032004
103. Flutamide [ep Monograph]
104. Schembl12932289
105. Hms501g21
106. Kbio1_000459
107. Kbio2_001690
108. Kbio2_004258
109. Kbio2_006826
110. Kbio3_002342
111. Flutamide [usp Monograph]
112. Ninds_000459
113. Hms1568d21
114. Hms1921o16
115. Hms2090i18
116. Hms2092o14
117. Hms2095d21
118. Hms2230p19
119. Hms3259i03
120. Hms3261p15
121. Hms3373c12
122. Hms3655g22
123. Hms3712d21
124. Pharmakon1600-01500995
125. Amy32524
126. Bcp23006
127. Hy-b0022
128. Zinc3812944
129. Tox21_110154
130. Tox21_202169
131. Tox21_300536
132. Tox21_500557
133. Bdbm50131270
134. Ccg-39105
135. M-propionotoluidide, 2-methyl-4'-nitro-alpha,alpha,alpha-triflouro-
136. M-propionotoluidide, Alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-
137. Nsc147834
138. Nsc215876
139. Nsc757817
140. S1908
141. Akos001025465
142. Akos025243203
143. M-propionotoluidide, .alpha.,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro-
144. Tox21_110154_1
145. Ab02835
146. Db00499
147. Ks-5091
148. Lp00557
149. Nc00451
150. Nsc-147834
151. Nsc-757817
152. Sdccgsbi-0050540.p004
153. Idi1_000459
154. Ncgc00015452-01
155. Ncgc00015452-02
156. Ncgc00015452-03
157. Ncgc00015452-04
158. Ncgc00015452-05
159. Ncgc00015452-06
160. Ncgc00015452-07
161. Ncgc00015452-08
162. Ncgc00015452-10
163. Ncgc00015452-11
164. Ncgc00015452-12
165. Ncgc00015452-13
166. Ncgc00015452-14
167. Ncgc00015452-15
168. Ncgc00015452-16
169. Ncgc00015452-19
170. Ncgc00015452-20
171. Ncgc00015452-32
172. Ncgc00091460-01
173. Ncgc00091460-02
174. Ncgc00091460-03
175. Ncgc00091460-04
176. Ncgc00091460-05
177. Ncgc00091460-06
178. Ncgc00091460-07
179. Ncgc00091460-08
180. Ncgc00091460-09
181. Ncgc00254495-01
182. Ncgc00259718-01
183. Ncgc00261242-01
184. Ac-24192
185. Bf166239
186. Sy036411
187. Sbi-0050540.p003
188. Db-042163
189. 3'-trifluoromethyl-4'-nitro-isobutyranilide
190. Ab00052188
191. Eu-0100557
192. Ft-0626493
193. Ft-0668764
194. Sw196536-4
195. 4''-nitro-3''-trifluoromethylisobutyranilide
196. C07653
197. D00586
198. Ab00052188-09
199. Ab00052188_10
200. Ab00052188_11
201. 311f847
202. A806562
203. Q418669
204. Q-201131
205. Sr-01000075888-1
206. Sr-01000075888-6
207. Sr-01000075888-7
208. Sr-01000075888-9
209. Brd-k28307902-001-05-0
210. Flutamide, Certified Reference Material, Tracecert(r)
211. Z56755651
212. A,a,a-trifluoro-2-methyl-4'-nitro- M-propionotoluidide
213. Flutamide, European Pharmacopoeia (ep) Reference Standard
214. 2-methyl-n-[4-nitro-3-(trifluoromethyl)phenyl]propanamide #
215. Flutamide, United States Pharmacopeia (usp) Reference Standard
216. 2-methyl-n-[4-nitro-3-(trifluoromethyl)phenyl]propanamide;flutamide
217. Alpha,alpha,alpha-trifluoro-2-methyl-4''-nitro-m-propionotoluidide
218. M-propionotoluidide, 2-methyl-4'-nitro-.alpha.,.alpha.,.alpha.-trifluoro-
219. Flutamide For System Suitability, European Pharmacopoeia (ep) Reference Standard
220. 37209-54-4
Molecular Weight | 276.21 g/mol |
---|---|
Molecular Formula | C11H11F3N2O3 |
XLogP3 | 3.3 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 2 |
Exact Mass | 276.07217670 g/mol |
Monoisotopic Mass | 276.07217670 g/mol |
Topological Polar Surface Area | 74.9 Ų |
Heavy Atom Count | 19 |
Formal Charge | 0 |
Complexity | 352 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Flutamide |
PubMed Health | Flutamide (By mouth) |
Drug Classes | Antiandrogen |
Drug Label | Flutamide capsules contain flutamide, an acetanilid, nonsteroidal, orally active antiandrogen having the chemical name, ,,-trifluoro-2-methyl-4'-nitrom-propionotoluidide.Each capsule contains 125 mg flutamide. The compound is a buff to yellow p... |
Active Ingredient | Flutamide |
Dosage Form | Capsule |
Route | Oral |
Strength | 125mg |
Market Status | Prescription |
Company | Actavis Labs Fl; Par Pharm; Ivax Sub Teva Pharms; Mylan |
2 of 2 | |
---|---|
Drug Name | Flutamide |
PubMed Health | Flutamide (By mouth) |
Drug Classes | Antiandrogen |
Drug Label | Flutamide capsules contain flutamide, an acetanilid, nonsteroidal, orally active antiandrogen having the chemical name, ,,-trifluoro-2-methyl-4'-nitrom-propionotoluidide.Each capsule contains 125 mg flutamide. The compound is a buff to yellow p... |
Active Ingredient | Flutamide |
Dosage Form | Capsule |
Route | Oral |
Strength | 125mg |
Market Status | Prescription |
Company | Actavis Labs Fl; Par Pharm; Ivax Sub Teva Pharms; Mylan |
For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate
FDA Label
Flutamide is a nonsteroidal antiandrogen. In animal studies, flutamide demonstrates potent antiandrogenic effects. It exerts its antiandrogenic action by inhibiting androgen uptake and/or by inhibiting nuclear binding of androgen in target tissues or both. Prostatic carcinoma is known to be androgen-sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen, e.g. castration. Elevations of plasma testosterone and estradiol levels have been noted following flutamide administration.
Antineoplastic Agents, Hormonal
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)
Androgen Antagonists
Compounds which inhibit or antagonize the biosynthesis or actions of androgens. (See all compounds classified as Androgen Antagonists.)
L02BB01
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
L - Antineoplastic and immunomodulating agents
L02 - Endocrine therapy
L02B - Hormone antagonists and related agents
L02BB - Anti-androgens
L02BB01 - Flutamide
Absorption
Rapidly and completely absorbed.
Route of Elimination
Flutamide and its metabolites are excreted mainly in the urine with only 4.2% of a single dose excreted in the feces over 72 hours.
Flutamide is rapidly and extensively metabolized, with flutamide comprising only 2.5% of plasma radioactivity 1 hour after administration.
Flutamide has known human metabolites that include 2-hydroxy-flutamide.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
The plasma half-life for the alpha-hydroxylated metabolite of flutamide (an active metabolite) is approximately 6 hours.
Flutamide is a nonsteroidal antiandrogen that blocks the action of both endogenous and exogenous testosterone by binding to the androgen receptor. In addition Flutamide is a potent inhibitor of testosterone-stimulated prostatic DNA synthesis. Moreover, it is capable of inhibiting prostatic nuclear uptake of androgen.
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Odyne manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Odyne, including repackagers and relabelers. The FDA regulates Odyne manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Odyne API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Odyne manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Odyne supplier is an individual or a company that provides Odyne active pharmaceutical ingredient (API) or Odyne finished formulations upon request. The Odyne suppliers may include Odyne API manufacturers, exporters, distributors and traders.
click here to find a list of Odyne suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Odyne DMF (Drug Master File) is a document detailing the whole manufacturing process of Odyne active pharmaceutical ingredient (API) in detail. Different forms of Odyne DMFs exist exist since differing nations have different regulations, such as Odyne USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Odyne DMF submitted to regulatory agencies in the US is known as a USDMF. Odyne USDMF includes data on Odyne's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Odyne USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Odyne suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Odyne Drug Master File in Japan (Odyne JDMF) empowers Odyne API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Odyne JDMF during the approval evaluation for pharmaceutical products. At the time of Odyne JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Odyne suppliers with JDMF on PharmaCompass.
A Odyne CEP of the European Pharmacopoeia monograph is often referred to as a Odyne Certificate of Suitability (COS). The purpose of a Odyne CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Odyne EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Odyne to their clients by showing that a Odyne CEP has been issued for it. The manufacturer submits a Odyne CEP (COS) as part of the market authorization procedure, and it takes on the role of a Odyne CEP holder for the record. Additionally, the data presented in the Odyne CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Odyne DMF.
A Odyne CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Odyne CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Odyne suppliers with CEP (COS) on PharmaCompass.
A Odyne written confirmation (Odyne WC) is an official document issued by a regulatory agency to a Odyne manufacturer, verifying that the manufacturing facility of a Odyne active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Odyne APIs or Odyne finished pharmaceutical products to another nation, regulatory agencies frequently require a Odyne WC (written confirmation) as part of the regulatory process.
click here to find a list of Odyne suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Odyne as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Odyne API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Odyne as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Odyne and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Odyne NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Odyne suppliers with NDC on PharmaCompass.
Odyne Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Odyne GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Odyne GMP manufacturer or Odyne GMP API supplier for your needs.
A Odyne CoA (Certificate of Analysis) is a formal document that attests to Odyne's compliance with Odyne specifications and serves as a tool for batch-level quality control.
Odyne CoA mostly includes findings from lab analyses of a specific batch. For each Odyne CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Odyne may be tested according to a variety of international standards, such as European Pharmacopoeia (Odyne EP), Odyne JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Odyne USP).
LOOKING FOR A SUPPLIER?